Schedule 13D ownership disclosure

CRISPR Therapeutics AG

Security class unavailable · CUSIP: H17182108

Event date: 2020-07-06

Legacy cover-page extraction is best effort and may not include every reporting person.

Filing-level shares
3,310,627
Percent of class
4.8000%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001387131-20-006322
Form type
SC 13D/A
Filer
CRISPR Therapeutics AG
CIK
CIK 1674416
Filed
Jul 10, 2020
Reporting period
Jul 06, 2020
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub